![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
20,247 Result(s)
-
Article
Open AccessTemplate-independent enzymatic synthesis of RNA oligonucleotides
RNA oligonucleotides have emerged as a powerful therapeutic modality to treat disease, yet current manufacturing methods may not be able to deliver on anticipated future demand. Here, we report the development...
-
Article
Enzymatic synthesis of RNA oligonucleotides
Research on enzymatic RNA synthesis has long been eclipsed by work on DNA—but a new method provides a leap forward for RNA.
-
Article
Open AccessPrecise in vivo RNA base editing with a wobble-enhanced circular CLUSTER guide RNA
Recruiting the endogenous editing enzyme adenosine deaminase acting on RNA (ADAR) with tailored guide RNAs for adenosine-to-inosine (A-to-I) RNA base editing is promising for safely manipulating genetic inform...
-
Article
CAR-Ts sweep into autoimmunity
Biotechs are equip** CAR-T cells to destroy B cells — not to treat blood cancers, but to take on multiple sclerosis and a raft of autoimmune disorders.
-
Article
Complete substitution with modified nucleotides in self-amplifying RNA suppresses the interferon response and increases potency
The use of modified nucleotides to suppress the interferon response and maintain translation of self-amplifying RNA (saRNA), which has been achieved for mRNA, has not yet succeeded. We identify modified nucleo...
-
Article
Programming tumor evolution with selection gene drives to proactively combat drug resistance
Most targeted anticancer therapies fail due to drug resistance evolution. Here we show that tumor evolution can be reproducibly redirected to engineer therapeutic opportunity, regardless of the exact ensemble ...
-
Article
Evolutionary gambit to defeat drug resistance in cancer
A therapeutic strategy harnesses evolutionary dynamics to overcome tumor resistance to targeted therapies.
-
Article
Editor’s pick: Unnatural Products
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Unnatural Products is rewriting the rules for potent oral therapies.
-
Article
Editor’s pick: Empress Therapeutics
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Empress Therapeutics is reverse-engineering microbial manufacturing.
-
Article
Open AccessHigh-throughput discovery of MHC class I- and II-restricted T cell epitopes using synthetic cellular circuits
Antigen discovery technologies have largely focused on major histocompatibility complex (MHC) class I-restricted human T cell receptors (TCRs), leaving methods for MHC class II-restricted and mouse TCR reactiv...
-
Article
Tracking-seq reveals the heterogeneity of off-target effects in CRISPR–Cas9-mediated genome editing
The continued development of novel genome editors calls for a universal method to analyze their off-target effects. Here we describe a versatile method, called Tracking-seq, for in situ identification of off-t...
-
Article
Author Correction: High-yield porphyrin production through metabolic engineering and biocatalysis
-
Article
Patient-derived mini-colons enable long-term modeling of tumor–microenvironment complexity
Existing organoid models fall short of fully capturing the complexity of cancer because they lack sufficient multicellular diversity, tissue-level organization, biological durability and experimental flexibili...
-
Article
miR-338-5p regulated the NF-κB/MAPK pathway to alleviate inflammation and oxidative stress by targeting IL-6 in rats with atrial fibrillation
The aim of this study was to investigate the functional effect of miR-338-5p targeting IL-6 on NF-κB/MAPK pathway-mediated inflammation and oxidative stress in atrial fibrillation (AF) rats. AF model rats were...
-
Article
Increasing access to biotech products for animal agriculture in Sub-Saharan Africa through partnerships
-
Article
In vivo AAV–SB-CRISPR screens of tumor-infiltrating primary NK cells identify genetic checkpoints of CAR-NK therapy
Natural killer (NK) cells have clinical potential against cancer; however, multiple limitations hinder the success of NK cell therapy. Here, we performed unbiased functional map** of tumor-infiltrating NK (T...
-
Article
Open AccessAuthor Correction: Identification of clinically relevant T cell receptors for personalized T cell therapy using combinatorial algorithms
-
Article
Open AccessCorrection: Characterization of two constitutive promoters RPS28 and EIF1 for studying soybean growth, development, and symbiotic nodule development
-
Article
Machine learning prediction of prime editing efficiency across diverse chromatin contexts
The success of prime editing depends on the prime editing guide RNA (pegRNA) design and target locus. Here, we developed machine learning models that reliably predict prime editing efficiency. PRIDICT2.0 asses...
-
Article
Effects of the first successful lawsuit against a consumer neurotechnology company for violating brain data privacy